Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Breast Cancer - Colon Cancer - Extrahepatic Bile Duct Cancer - Gallbladder Cancer - Gastrointestinal Cancer - Liver and Intrahepatic Biliary Tract Cancer - Lung Cancer - Metastatic Cancer - Pancreatic Cancer - Rectal Cancer - Thyroid Gland Medullary Carcinoma - Unspecified Adult Solid Tumor, Protocol Specific
Conditions: official terms
Bile Duct Neoplasms - Biliary Tract Neoplasms - Carcinoma, Medullary - Cholangiocarcinoma - Gastrointestinal Neoplasms - Neoplasm Metastasis - Pancreatic Neoplasms - Thyroid Neoplasms
Study Type
Study Phase
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Name: radionuclide imaging Type: Procedure
Name: positron emission tomography Type: Procedure
Name: laboratory biomarker analysis Type: Other
Name: pharmacological study Type: Other
Name: Cu 64 anti-CEA monoclonal antibody M5A IV Type: Drug
Overall Status
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may help find and diagnose CEA positive cancer that may not be detected by standard diagnostic methods.
Detailed Description

I. To determine the ability of 64Cu labeled M5A antibody (copper Cu 64 anti-CEA monoclonal antibody M5A) to localize CEA positive cancers (such as gastrointestinal, lung, medullary thyroid and breast cancers), as determined by PET imaging.


I. To characterize the frequency of titer of the human anti-human antibody (HAHA) response to 64Cu labeled M5A antibody.

II. To determine the safety of administration of 64Cu labeled M5A antibody.


Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A intravenously (IV) on day 0 and then undergo PET on day 1 (18-24 hours post-injection) and day 2 (42-48 hours post-injection).

After completion of study, patients are followed up at 1 and 3 months.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients must have histologically confirmed primary or metastatic cancer; if biopsies were performed at an outside facility, the histology must be reviewed and confirmed by the Department of Pathology at the City of Hope

- Patients must have tumors that produce CEA as documented by a current or past history of an elevated serum CEA above the institutional limit of normal; NOTE: Patients with colorectal cancer are exempt from this requirement since > 95% are CEA positive

- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

- Patients must have a known site of disease

- Although not mandated by the protocol, the results of the CT scan and labs (complete blood count [CBC], comprehensive metabolic panel [CMP]) that are performed as part of the standard work up should be available and should have been done within 2 months prior to study entry

- All subjects must have the ability to understand and the willingness to sign a written informed consent

- Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 4 weeks prior to infusion of radiolabeled antibody

Exclusion Criteria:

- Patients should not have any uncontrolled illness including ongoing or active infection

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu 64 anti-CEA monoclonal antibody M5A (64Cu-M5A)

- Patients must not have received prior chemotherapy or radiation for >= 4 weeks before study enrollment

- Pregnant women are excluded from this study; breastfeeding should be discontinued is the mother is treated with 54Cu-m5A

- Any patient who has had exposure to mouse or chimeric (human/mouse) immunoglobulin and has antibody to the M5A

- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
City of Hope Medical Center
Duarte, California, United States
Status: Recruiting
Contact: Jeffrey Y. Wong - 800-826-4673
Start Date
June 2015
City of Hope Medical Center
City of Hope Medical Center
Record processing date processed this data on July 28, 2015 page